Vinorelbine With Pertuzumab and Trastuzumab as First-Line Treatment in Patients With HER2-Positive Breast Cancer

Pertuzumab and trastuzumab given with a taxane is recommended by NCCN guidelines for the first-line treatment of patients with HER2-positive metastatic breast cancer. This recommendation is largely based on the CLEOPATRA study, which demonstrated a PFS and OS advantage to adding pertuzumab.

 Practice Update

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.